Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus

Cardiology

Volumn 116, Issue 1, 2010, Pages 51-57

  Ueda, Hiroyasu ^a   Mitsusada, Nobuhiro ^a   Harimoto, Kuniyasu ^a   Miyawaki, Masami ^a   Yasuga, Yuji ^a   Hiraoka, Hisatoyo ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

Drug eluting stent; Hemoglobin A1c; Major adverse cardiac events

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL; RAPAMYCIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART INFARCTION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77951951239     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314331     Document Type: Article

References (23)

1. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341-346.
2. Dunn PJ, Cole RA, Soeldner JS, Gleason RE: Reproducibility of hemoglobin AIc and sensitivity to various degrees of glucose intolerance. Ann Intern Med 1979; 91: 390-396.
3. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPICNorfolk). BMJ 2001; 322: 15-18.
4. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
5. Gerstein HC, Swedberg K, Carlsson J, Mc- Murray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S, CHARM Program Investigators: The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008; 168: 1699-1704.
6. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, Timmis GC, Balasubramaniam M, O'Neill WW: Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8-14.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
8. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, Ibrahim M, Schömig A, Kastrati A: Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007; 154: 688-693.
9. Park DW, Flaherty JD, Davidson CJ, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ: Prognostic influence of diabetes mellitus on longterm clinical outcomes and stent thrombosis after drug-eluting stent implantation in Asian patients. Am J Cardiol 2009; 103: 646-652.
10. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A: Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxeleluting stents. J Am Coll Cardiol 2006; 48: 1304-1309.
11. Wolfram RM, Brewer HB, Xue Z, Satler LF, Pichard AD, Kent KM, Waksman R: Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 2006; 98: 711-717.
12. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ: Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 2007; 93: 1087-1092.
13. Hasdai D, Rizza RA, Grill DE, Scott CG, Garratt KN, Holmes DR Jr: Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization. Am Heart J 2001; 141: 117-123.
14. Lemesle G, Bonello L, de Labriolle A, Maluenda G, Syed AI, Collins SD, Ben-Dor I, Torguson R, Kaneshige K, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R: Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol 2009; 104: 41-45.
15. Stankovic G, Cosgrave J, Chieffo A, Iakovou I, Sangiorgi G, Montorfano M, Airoldi F, Carlino M, Michev I, Finci L, Colombo A: Impact of sirolimus-eluting and paclitaxeleluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 2006; 98: 362-366.
16. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L: Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334-341. (Pubitemid 41043777)
17. Nishio K, Fukui T, Tsunoda F, Kawamura K, Itoh S, Konno N, Ozawa K, Katagiri T: Insulin resistance as a predictor for restenosis after coronary stenting. Int J Cardiol 2005; 103: 128-134.
18. Haffner SM, Alexander CM, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K: Reduced coronary events in simvastatin- treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661-2667.
19. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, LIPID Study Group: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
20. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo- controlled trial. Lancet 2003; 361: 2005-2016.
21. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004; 364: 685-696.
22. Smith SC Jr, Faxon D, Cascio W, Schaff H, Gardner T, Jacobs A, Nissen S, Stouffer R: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. Circulation 2002; 105:e165-e169.
23. Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, Caldwell RW: Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 2006; 319: 386-395.